Trial Profile
A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Lisocabtagene-maraleucel (Primary) ; Carboplatin; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Fludarabine; Gemcitabine; Ifosfamide; Melphalan; Rituximab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms TRANSFORM
- Sponsors Celgene Corporation
- 12 Dec 2023 Results to assess post infusion monitoring-related HCRU identify from pooled TRANSFORM and PILOT studies, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results of analysis assessing HCRU and costs for managing CRS and/or NEs after liso-cel administration among patients with R/R large B-cell lymphoma (LBCL) treated with liso-cel as 2L therapy in two clinical studies: TRANSFORM and PILOT presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results assessing longitudinally measured ctDNA levels from TRANSFORM as a prospective measure of disease burden and describe the predictive value of ctDNA after 2L liso-cel therapy for LBCL were presented at the 65th American Society of Hematology Annual Meeting and Exposition.